Stocks · News reference
Filed: 2026-09-14 AccNo: 0001671927-26-000026 Size: 491 KB Item 7.01: Regulation FD Disclosure Item 9.01: Financial Statements and Exhibits
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Immunocore Hldgs (NASDAQ:IMCR) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to
Immunocore announced it has enrolled 540 patients in the phase III TEBE-AM study evaluating Kimmtrak as monotherapy and in combination with Merck's Keytruda versus investigator's choice in previously treated advanced melanoma. The company expects top-line overall survival data as early as end of 2026. Kimmtrak sales grew 16% year-over-year to $222.6 million in the first half of 2026.
Immunocore Holdings plc (NASDAQ:IMCR) ("Immunocore" or the "Company"), a commercial-stage biotechnology company pioneering and delivering transformative immunomodulating medicines to radically improve